Related Experiment Video
Updated: May 28, 2026

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
Published on: May 6, 2014
Increased circulating plasma lysophosphatidic acid in patients with acute coronary syndrome
Tomotaka Dohi1, Katsumi Miyauchi, Ryunosuke Ohkawa
1Department of Cardiovascular Medicine, Juntendo University School of Medicine, Tokyo, Japan. tdohi@juntendo.ac.jp
Background:
The platelet activator lysophosphatidic acid (LPA) has recently been identified as an ingredient in oxidized LDL and it has been isolated from atherosclerotic plaques. The lysophospholipase D activity of autotaxin produces LPA extracellularly from lysophosphatidylcholine (LPC). The present study determines whether circulating LPA is associated with acute coronary syndrome (ACS).
Methods:
We enrolled 141 consecutive patients (age, 62.6±3.8 y; male, 69.2%) with ACS (n=38), stable angina pectoris (SAP; n=72) or angiographically normal coronary arteries (NCA; n=31). The relationships between LPA and other established biomarkers were examined. Concentrations of plasma LPA were determined using an enzymatic assay.
Results:
Concentrations of LPA significantly correlated with LPC (r=0.549), autotaxin (r=0.370) and LDL-C (r=0.307) (all p<0.01). Lysophosphatidic acid concentrations were significantly higher in patients with ACS than with SAP and NCA (p<0.01), but did not significantly differ between patients with SAP and NCA. Multivariate logistic regression analyses revealed that the highest LPA tertile was independently associated with ACS (odds ratio 1.99, 95% CI: 1.18-3.39, p=0.02).
Conclusions:
The present study demonstrated that increased circulating plasma LPA concentrations are significantly associated with ACS.
Related Concept Videos
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Coronary Artery Disease II: Pathophysiology
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome I: Introduction
Peripheral Artery Disease I: Introduction
Atherosclerosis III: Management